Literature DB >> 8886876

Symposium: ovarian tumors of borderline malignancy.

E G Silva1, R J Kurman, P Russell, R E Scully.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8886876

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN： 0277-1691            Impact factor:   2.762


× No keyword cloud information.
  7 in total

1.  The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.

Authors:  Sergio Marchini; Elizabeth Poynor; Richard R Barakat; Luca Clivio; Michela Cinquini; Robert Fruscio; Luca Porcu; Cecilia Bussani; Maurizio D'Incalci; Eugenio Erba; Michela Romano; Giorgio Cattoretti; Dionyssios Katsaros; Andrew Koff; Lucio Luzzatto
Journal:  Clin Cancer Res       Date:  2012-06-25       Impact factor: 12.531

2.  Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Authors:  Kruti P Maniar; Yihong Wang; Kala Visvanathan; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

3.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

4.  Risk factors for recurrence of ovarian borderline tumors.

Authors:  K K Shih; Q Zhou; J Huh; J C Morgan; A Iasonos; C Aghajanian; D S Chi; R R Barakat; N R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-12-10       Impact factor: 5.482

5.  Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.

Authors:  Yoon-La Choi; So Young Kang; Young Kee Shin; Jong Sun Choi; Seok Hyung Kim; Sun-Joo Lee; Duk-Soo Bae; Geunghwan Ahn
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

6.  Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.

Authors:  Karin K Shih; Qin C Zhou; Carol Aghajanian; Jae Huh; Robert A Soslow; Jessica C Morgan; Alexia Iasonos; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2010-08-16       Impact factor: 5.482

7.  Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Authors:  Michael S Anglesio; Jeremy M Arnold; Joshy George; Anna V Tinker; Richard Tothill; Nic Waddell; Lisa Simms; Bianca Locandro; Sian Fereday; Nadia Traficante; Peter Russell; Raghwa Sharma; Michael J Birrer; Anna deFazio; Georgia Chenevix-Trench; David D L Bowtell
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.